Addressing 'Drug Loss' in Japan: Urgent Need to Strengthen New Drug Development
Currently, the issue of "drug loss" has become a major concern in Japan. This refers to a situation where new drugs developed overseas are not approved in Japan, remaining unavailable for use. As this means patients may be unable to receive the latest treatments, an urgent response is required.
To improve this situation, the government, industry, and universities have begun collaborating to explore ways to strengthen the nation's drug discovery capabilities. A key to the solution lies in Japan becoming a preferred country for global pharmaceutical companies to conduct clinical trials.
By actively participating in international joint clinical trials, Japan can ensure that the latest overseas drugs become available domestically much faster. To achieve this, it is necessary to streamline the clinical trial framework and increase the benefits of conducting research and development within Japan.
Through this integrated effort between industry, government, and academia, Japan's medical landscape is on the verge of significant change. It is hoped that the speed of new drug development will increase, allowing many more patients to have access to new treatment options.